-
1
-
-
0035079648
-
Epidemiology of the myeloproliferative disorders: Essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis
-
Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001;49(2):164-6
-
(2001)
Pathol Biol (Paris)
, vol.49
, Issue.2
, pp. 164-166
-
-
Kutti, J.1
Ridell, B.2
-
2
-
-
0026649984
-
High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel
-
Chaiter Y, Brenner B, Aghai E, et al. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992;7(3):251-5
-
(1992)
Leuk Lymphoma
, vol.7
, Issue.3
, pp. 251-255
-
-
Chaiter, Y.1
Brenner, B.2
Aghai, E.3
-
3
-
-
0026069267
-
Mortality patterns among petroleum refinery and chemical plant workers
-
Marsh GM, Enterline PE, McCraw D. Mortality patterns among petroleum refinery and chemical plant workers. Am J Ind Med 1991;19(1):29-42
-
(1991)
Am J Ind Med
, vol.19
, Issue.1
, pp. 29-42
-
-
Marsh, G.M.1
Enterline, P.E.2
McCraw, D.3
-
4
-
-
84879104781
-
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
-
Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 2013;54(9):1989-95
-
(2013)
Leuk Lymphoma
, vol.54
, Issue.9
, pp. 1989-1995
-
-
Stein, B.L.1
Saraf, S.2
Sobol, U.3
-
5
-
-
84883742082
-
Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study
-
Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27(9):1874-81
-
(2013)
Leukemia
, vol.27
, Issue.9
, pp. 1874-1881
-
-
Tefferi, A.1
Rumi, E.2
Finazzi, G.3
-
6
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
-
(2005)
Nature
, vol.434
, Issue.7037
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le Couedic, J.P.3
-
7
-
-
21344467318
-
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
-
Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106(6):2162-8
-
(2005)
Blood
, vol.106
, Issue.6
, pp. 2162-2168
-
-
Jones, A.V.1
Kreil, S.2
Zoi, K.3
-
8
-
-
33846660947
-
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
-
Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356(5):459-68
-
(2007)
N Engl J Med
, vol.356
, Issue.5
, pp. 459-468
-
-
Scott, L.M.1
Tong, W.2
Levine, R.L.3
-
9
-
-
84919467186
-
Presence of calreticulin mutations in JAK2-negative polycythemia vera
-
Broseus J, Park JH, Carillo S, et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014;124(26):3964-6
-
(2014)
Blood
, vol.124
, Issue.26
, pp. 3964-3966
-
-
Broseus, J.1
Park, J.H.2
Carillo, S.3
-
10
-
-
34548042964
-
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel
-
Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110(4):1092-7
-
(2007)
Blood
, vol.110
, Issue.4
, pp. 1092-1097
-
-
Tefferi, A.1
Thiele, J.2
Orazi, A.3
-
11
-
-
84893964717
-
Masked polycythemia vera diagnosed according to WHO and BCSH classification
-
Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89(2):199-202
-
(2014)
Am J Hematol
, vol.89
, Issue.2
, pp. 199-202
-
-
Barbui, T.1
Thiele, J.2
Carobbio, A.3
-
12
-
-
34548152255
-
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis
-
McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007;138(6):821-2
-
(2007)
Br J Haematol
, vol.138
, Issue.6
, pp. 821-822
-
-
McMullin, M.F.1
Reilly, J.T.2
Campbell, P.3
-
13
-
-
84904067758
-
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
-
Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28(7):1407-13
-
(2014)
Leukemia
, vol.28
, Issue.7
, pp. 1407-1413
-
-
Tefferi, A.1
Thiele, J.2
Vannucchi, A.M.3
-
14
-
-
84887373344
-
Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis
-
Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122(11):1881-6
-
(2013)
Blood
, vol.122
, Issue.11
, pp. 1881-1886
-
-
Silver, R.T.1
Chow, W.2
Orazi, A.3
-
15
-
-
34249949626
-
Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
-
Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33(4):313-20
-
(2007)
Semin Thromb Hemost
, vol.33
, Issue.4
, pp. 313-320
-
-
Tefferi, A.1
Elliott, M.2
-
16
-
-
84871746842
-
Cardiovascular events and intensity of treatment in polycythemia vera
-
Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22-33
-
(2013)
N Engl J Med
, vol.368
, Issue.1
, pp. 22-33
-
-
Marchioli, R.1
Finazzi, G.2
Specchia, G.3
-
17
-
-
0346727336
-
Efficacy and safety of low-dose aspirin in polycythemia vera
-
Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350(2):114-24
-
(2004)
N Engl J Med
, vol.350
, Issue.2
, pp. 114-124
-
-
Landolfi, R.1
Marchioli, R.2
Kutti, J.3
-
18
-
-
79551491928
-
Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
-
Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761-70
-
(2011)
J Clin Oncol
, vol.29
, Issue.6
, pp. 761-770
-
-
Barbui, T.1
Barosi, G.2
Birgegard, G.3
-
19
-
-
43949103121
-
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
-
Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22(5):905-14
-
(2008)
Leukemia
, vol.22
, Issue.5
, pp. 905-914
-
-
Cervantes, F.1
Passamonti, F.2
Barosi, G.3
-
20
-
-
84874959297
-
Polycythemia vera: Current pharmacotherapy and future directions
-
Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14(5):609-17
-
(2013)
Expert Opin Pharmacother
, vol.14
, Issue.5
, pp. 609-617
-
-
Hensley, B.1
Geyer, H.2
Mesa, R.3
-
21
-
-
0031041044
-
From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera
-
Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34(1):17-23
-
(1997)
Semin Hematol
, vol.34
, Issue.1
, pp. 17-23
-
-
Fruchtman, S.M.1
Mack, K.2
Kaplan, M.E.3
-
22
-
-
84859922985
-
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
-
Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012;87(5):552-4
-
(2012)
Am J Hematol
, vol.87
, Issue.5
, pp. 552-554
-
-
Antonioli, E.1
Guglielmelli, P.2
Pieri, L.3
-
23
-
-
77649227181
-
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European LeukemiaNet (ELN) consensus process
-
Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010;148(6):961-3
-
(2010)
Br J Haematol
, vol.148
, Issue.6
, pp. 961-963
-
-
Barosi, G.1
Birgegard, G.2
Finazzi, G.3
-
24
-
-
66549086134
-
Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference
-
Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113(20):4829-33
-
(2009)
Blood
, vol.113
, Issue.20
, pp. 4829-4833
-
-
Barosi, G.1
Birgegard, G.2
Finazzi, G.3
-
25
-
-
79959203501
-
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
-
Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410-15
-
(2011)
J Clin Oncol
, vol.29
, Issue.17
, pp. 2410-2415
-
-
Bjorkholm, M.1
Derolf, A.R.2
Hultcrantz, M.3
-
26
-
-
80053945428
-
Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980
-
Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29(29):3907-13
-
(2011)
J Clin Oncol
, vol.29
, Issue.29
, pp. 3907-3913
-
-
Kiladjian, J.J.1
Chevret, S.2
Dosquet, C.3
-
27
-
-
79952980528
-
Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders
-
Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011;11(3):403-14
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, Issue.3
, pp. 403-414
-
-
Spivak, J.L.1
Hasselbalch, H.2
-
28
-
-
0016492795
-
Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys
-
Wilson JG, Scott WJ, Ritter EJ, et al. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology 1975;11(2):169-78
-
(1975)
Teratology
, vol.11
, Issue.2
, pp. 169-178
-
-
Wilson, J.G.1
Scott, W.J.2
Ritter, E.J.3
-
29
-
-
46849120215
-
Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males
-
Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93(7):988-93
-
(2008)
Haematologica
, vol.93
, Issue.7
, pp. 988-993
-
-
Berthaut, I.1
Guignedoux, G.2
Kirsch-Noir, F.3
-
30
-
-
56249104095
-
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
-
Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22(11):1990-8
-
(2008)
Leukemia
, vol.22
, Issue.11
, pp. 1990-1998
-
-
Kiladjian, J.J.1
Chomienne, C.2
Fenaux, P.3
-
31
-
-
84908022970
-
Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation
-
Huang BT, Zeng QC, Zhao WH. Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 2014;38(10):1177-83
-
(2014)
Leuk Res
, vol.38
, Issue.10
, pp. 1177-1183
-
-
Huang, B.T.1
Zeng, Q.C.2
Zhao, W.H.3
-
32
-
-
33746307253
-
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
-
Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107(3):451-8
-
(2006)
Cancer
, vol.107
, Issue.3
, pp. 451-458
-
-
Silver, R.T.1
-
33
-
-
84867261125
-
Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
-
Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97(10):1570-3
-
(2012)
Haematologica
, vol.97
, Issue.10
, pp. 1570-1573
-
-
Gowin, K.1
Thapaliya, P.2
Samuelson, J.3
-
34
-
-
81255210738
-
A new era for IFNalpha in the treatment of Philadelphianegative chronic myeloproliferative neoplasms
-
Hasselbalch HC. A new era for IFNalpha in the treatment of Philadelphianegative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4(6):637-55
-
(2011)
Expert Rev Hematol
, vol.4
, Issue.6
, pp. 637-655
-
-
Hasselbalch, H.C.1
-
36
-
-
54049141336
-
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
-
Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065-72
-
(2008)
Blood
, vol.112
, Issue.8
, pp. 3065-3072
-
-
Kiladjian, J.J.1
Cassinat, B.2
Chevret, S.3
-
37
-
-
73949090770
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
-
Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27(32):5418-24
-
(2009)
J Clin Oncol
, vol.27
, Issue.32
, pp. 5418-5424
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Manshouri, T.3
-
38
-
-
8544265328
-
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera
-
Stasi R, Brunetti M, Bussa S, et al. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera. J Intern Med 1997;242(2):143-7
-
(1997)
J Intern Med
, vol.242
, Issue.2
, pp. 143-147
-
-
Stasi, R.1
Brunetti, M.2
Bussa, S.3
-
39
-
-
0031978967
-
Role of human leukocyte interferonalpha in the treatment of patients with polycythemia vera
-
Stasi R, Venditti A, Del Poeta G, et al. Role of human leukocyte interferonalpha in the treatment of patients with polycythemia vera. Am J Med Sci 1998;315(4):237-41
-
(1998)
Am J Med Sci
, vol.315
, Issue.4
, pp. 237-241
-
-
Stasi, R.1
Venditti, A.2
Del Poeta, G.3
-
40
-
-
0023946455
-
Anagrelide: A new drug for treating thrombocytosis
-
Silverstein MN, Petitt RM, Solberg LA Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318(20):1292-4
-
(1988)
N Engl J Med
, vol.318
, Issue.20
, pp. 1292-1294
-
-
Silverstein, M.N.1
Petitt, R.M.2
Solberg, L.A.3
-
41
-
-
14744274434
-
Anagrelide: Analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders
-
Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29(5):481-91
-
(2005)
Leuk Res
, vol.29
, Issue.5
, pp. 481-491
-
-
Fruchtman, S.M.1
Petitt, R.M.2
Gilbert, H.S.3
-
42
-
-
31444454549
-
Anagrelide: A review of its use in the management of essential thrombocythaemia
-
Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006;66(1):111-31
-
(2006)
Drugs
, vol.66
, Issue.1
, pp. 111-131
-
-
Wagstaff, A.J.1
Keating, G.M.2
-
43
-
-
0001865775
-
A polycythemia vera updated: Diagnosis, pathobiology, and treatment
-
Pearson TC, Messinezy M, Westwood N, et al. A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology Am Soc Hematol Educ Program 2000(1):51-68
-
(2000)
Hematology Am Soc Hematol Educ Program
, Issue.1
, pp. 51-68
-
-
Pearson, T.C.1
Messinezy, M.2
Westwood, N.3
-
44
-
-
84929167678
-
Phase i study results of a novel controlled-release formulation of anagrelide (GALE-401) for the treatment of thrombocytosis
-
Laliberte R GP, Hamilton B. Phase I study results of a novel controlled-release formulation of anagrelide (GALE-401) for the treatment of thrombocytosis. Blood ASH Abstracts 2014;124:21
-
(2014)
Blood ASH Abstracts
, vol.124
, pp. 21
-
-
Laliberte, R.G.P.1
Hamilton, B.2
-
45
-
-
84889044017
-
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide
-
Ahn IE, Natelson E, Rice L. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk 2013;13(Suppl 2):S300-4
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. S300-S304
-
-
Ahn, I.E.1
Natelson, E.2
Rice, L.3
-
46
-
-
0022703490
-
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
-
Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23(2):132-43
-
(1986)
Semin Hematol
, vol.23
, Issue.2
, pp. 132-143
-
-
Berk, P.D.1
Goldberg, J.D.2
Donovan, P.B.3
-
47
-
-
84922917634
-
Target hematologic values in the management of essential thrombocythemia and polycythemia vera
-
Hernandez-Boluda JC, Gomez M. Target hematologic values in the management of essential thrombocythemia and polycythemia vera. Euro J Haematol 2015;94(1):4-1
-
(2015)
Euro J Haematol
, vol.94
, Issue.1
, pp. 4-1
-
-
Hernandez-Boluda, J.C.1
Gomez, M.2
-
48
-
-
84909584695
-
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
-
Wang X, Ye F, Tripodi J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood 2014;124(19):2987-95
-
(2014)
Blood
, vol.124
, Issue.19
, pp. 2987-2995
-
-
Wang, X.1
Ye, F.2
Tripodi, J.3
-
49
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
50
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.J.2
Al-Ali, H.K.3
-
51
-
-
84893733177
-
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
-
Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120(4):513-20
-
(2014)
Cancer
, vol.120
, Issue.4
, pp. 513-520
-
-
Verstovsek, S.1
Passamonti, F.2
Rambaldi, A.3
-
52
-
-
84928476375
-
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
-
Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35
-
(2015)
N Engl J Med
, vol.372
, Issue.5
, pp. 426-435
-
-
Vannucchi, A.M.1
Kiladjian, J.J.2
Griesshammer, M.3
-
53
-
-
84892882122
-
Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis?
-
Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013;122(23):3843-4
-
(2013)
Blood
, vol.122
, Issue.23
, pp. 3843-3844
-
-
Heine, A.1
Brossart, P.2
Wolf, D.3
-
54
-
-
20144389274
-
Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study
-
Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105(7):2664-70
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2664-2670
-
-
Finazzi, G.1
Caruso, V.2
Marchioli, R.3
-
55
-
-
84922264206
-
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
-
Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 2014;93(12):2037-43
-
(2014)
Ann Hematol
, vol.93
, Issue.12
, pp. 2037-2043
-
-
Alvarez-Larran, A.1
Martinez-Aviles, L.2
Hernandez-Boluda, J.C.3
|